logo
logo
HomeAbout UsPlatformInsights

Clinical Trial Insights

AllClinical TrialRegulatoryMerger & AcquisitionsBlogs
Sanofi/Ad Scientiam Presents Interim MS-DETECT Data on MS Copilot for Disease MonitoringClinical Trial Updates

01 Jul 2026

Sanofi/Ad Scientiam Presents Interim MS-DETECT Data on MS Copilot for Disease Monitoring

Sanofi and Ad Scientiam presented interim analysis from the ongoing MS-DETECT study (NCT05816122) at the 12th Congress of the European Academy of Neurology...

Catalyst Pharmaceuticals Announces Positive Topline Results from Phase 1 Vamorolone StudyClinical Trial Updates

01 Jul 2026

Catalyst Pharmaceuticals Announces Positive Topline Results from Phase 1 Vamorolone Study

Catalyst Pharmaceuticals, Inc. reported positive topline results from a two-part Phase 1 clinical study of vamorolone in healthy adult volunteers. The study...

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH TrialClinical Trial Updates

01 Jul 2026

Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

Ascendis Pharma announced new radiographic data from Week 104 of the pivotal ApproaCH Trial for once-weekly TransCon CNP (navepegritide) in children with...

Genmab and AbbVie’s Epkinly Combo Improves PFS in Second-Line DLBCL TrialClinical Trial Updates

01 Jul 2026

Genmab and AbbVie’s Epkinly Combo Improves PFS in Second-Line DLBCL Trial

Genmab and AbbVie announced that their Phase III EPCORE DLBCL-4 trial, investigating a fixed-duration combination of Epkinly (epcoritamab) and Bristol Myers...

Evommune Ends Development of Lead Asset in Chronic Hives After Mid-Stage Efficacy WoesClinical Trial Updates

01 Jul 2026

Evommune Ends Development of Lead Asset in Chronic Hives After Mid-Stage Efficacy Woes

Evommune has halted development of its lead asset, EVO756, for chronic spontaneous urticaria following a Phase 2b study that showed no significant benefit. The...

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than ControlClinical Trial Updates

01 Jul 2026

Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control

Moleculin Biotech announced positive preliminary unblinded efficacy results from the first 45 patients in Part A of its pivotal Phase 2/3 MIRACLE trial for...

Regeneron highlights disease control potential of cemdisiran in gMGClinical Trial Updates

01 Jul 2026

Regeneron highlights disease control potential of cemdisiran in gMG

Regeneron's Phase III NIMBLE study (NCT05070858) demonstrated positive topline data for cemdisiran in generalized myasthenia gravis (gMG). The trial met its...

Skyhawk CEO hopes FDA’s new uniQure position will translate to Huntington’s pillClinical Trial Updates

01 Jul 2026

Skyhawk CEO hopes FDA’s new uniQure position will translate to Huntington’s pill

Skyhawk Therapeutics revealed 12-month functional data from a Phase 1/2 trial of its oral drug, SKY-0515, for Huntington's disease. The data showed "favorable...

Natera, Aveta Biomics collaborate on head and neck cancer trialClinical Trial Updates

01 Jul 2026

Natera, Aveta Biomics collaborate on head and neck cancer trial

Natera and Aveta Biomics have partnered for the AVTA 30-01, a global Phase III clinical trial assessing APG-157, an oral immunotherapy, in patients with...

NeuroSense’s ALS drug cuts key biomarker in Phase IIb trialClinical Trial Updates

29 Jun 2026

NeuroSense’s ALS drug cuts key biomarker in Phase IIb trial

NeuroSense Therapeutics' combination ALS therapy, PrimeC, demonstrated a statistically significant reduction in TDP-43 protein levels, a key biomarker for ALS...

Evommune terminates oral drug’s development in CSUClinical Trial Updates

29 Jun 2026

Evommune terminates oral drug’s development in CSU

Evommune announced the termination of development for its oral MRGPRX2 antagonist, EVO756, in chronic spontaneous urticaria (CSU) after the drug failed to meet...

BridgeBio’s Achondroplasia Pill Shows ‘Compelling’ Growth and Body Proportionality BenefitClinical Trial Updates

29 Jun 2026

BridgeBio’s Achondroplasia Pill Shows ‘Compelling’ Growth and Body Proportionality Benefit

BridgeBio Pharma's oral drug, infigratinib, demonstrated significant improvements in both growth velocity and body proportionality in children with...

Summit Therapeutics and Akeso's Harmoni-3 Trial Results Anticipated in H2 2026Clinical Trial Updates

29 Jun 2026

Summit Therapeutics and Akeso's Harmoni-3 Trial Results Anticipated in H2 2026

Results from the global Harmoni-3 trial, evaluating the combination of ivonescimab and chemotherapy for frontline non-small cell lung cancer (NSCLC), are...

GSK's Mo-Rez Shows Promising Phase 1 Data in Ovarian and Endometrial CancersClinical Trial Updates

29 Jun 2026

GSK's Mo-Rez Shows Promising Phase 1 Data in Ovarian and Endometrial Cancers

GSK's novel antibody-drug conjugate (ADC) mocertatug rezetecan (Mo-Rez), targeting B7-H4, demonstrated encouraging results in its Phase 1 BEHOLD-1...

Corxel to advance oral obesity drug to Phase III trialsClinical Trial Updates

25 Jun 2026

Corxel to advance oral obesity drug to Phase III trials

Corxel Pharmaceuticals announced positive Phase II results for its oral GLP-1RA candidate, CX11, in the US, paving the way for global pivotal Phase III...

To Wall Street, psychedelics biotechs are more teammates than rivalsClinical Trial Updates

25 Jun 2026

To Wall Street, psychedelics biotechs are more teammates than rivals

Definium Therapeutics announced positive late-stage trial data for its LSD formulation, demonstrating significant efficacy over placebo in relieving symptoms...

ADC Therapeutics lays off staff after 27 patient deaths mar Zynlonta readoutClinical Trial Updates

25 Jun 2026

ADC Therapeutics lays off staff after 27 patient deaths mar Zynlonta readout

ADC Therapeutics is implementing layoffs for approximately 30 workers, or 17% of its team, following disappointing results from its LOTIS-5 Phase 3 trial for...

MSD’s anti-TL1A mAb from $10.8bn acquisition wins in Phase III trialClinical Trial Updates

24 Jun 2026

MSD’s anti-TL1A mAb from $10.8bn acquisition wins in Phase III trial

MSD's investigational humanised monoclonal antibody, tulisokibart, acquired through a $10.8 billion buyout of Prometheus Therapeutics, has successfully met all...

GondolaBio Reports Positive Data from Phase IIa Trial of PORT-77Clinical Trial Updates

24 Jun 2026

GondolaBio Reports Positive Data from Phase IIa Trial of PORT-77

GondolaBio announced positive results from its Phase IIa GATEWAY study of PORT-77, an oral ABCG2 inhibitor, for erythropoietic protoporphyria (EPP) and...

Merck posts ‘encouraging’ Phase 3 ulcerative colitis data but Roche challenge loomsClinical Trial Updates

24 Jun 2026

Merck posts ‘encouraging’ Phase 3 ulcerative colitis data but Roche challenge looms

Merck's investigational antibody, tulisokibart, an intravenous TL1A inhibitor, successfully met its primary endpoint of clinical remission at 12 weeks in a...

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)Clinical Trial Updates

24 Jun 2026

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Phathom Pharmaceuticals has successfully completed patient enrollment in its Phase 2 pHalcon-EoE-201 clinical trial, evaluating VOQUEZNA (vonoprazan) tablets...

Elevar Therapeutics Announces First Patients Dosed in Phase 2 Study of Lirafugratinib Among Non-CCA Solid Tumors With FGFR2 Fusion or RearrangementClinical Trial Updates

22 Jun 2026

Elevar Therapeutics Announces First Patients Dosed in Phase 2 Study of Lirafugratinib Among Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

Elevar Therapeutics has initiated its global Phase 2 ReFocus202 study of lirafugratinib, dosing the first patients in Seoul, South Korea, and Tampa, Florida....

Merck's Tulisokibart Succeeds in Phase 3 Ulcerative Colitis TrialClinical Trial Updates

22 Jun 2026

Merck's Tulisokibart Succeeds in Phase 3 Ulcerative Colitis Trial

Merck & Co.'s experimental drug, tulisokibart, has successfully met its primary goal in a Phase 3 study for moderately to severely active ulcerative colitis....

Definium’s LSD-based therapy elicits ‘profound’ efficacy in Phase 3 depression trialClinical Trial Updates

22 Jun 2026

Definium’s LSD-based therapy elicits ‘profound’ efficacy in Phase 3 depression trial

Definium Therapeutics' oral psychedelic treatment, DT120 (an LSD formulation), achieved all primary and secondary endpoints in its Phase 3 Emerge trial for...

UniQure’s chronic epilepsy gene therapy ‘should be on investors’ radar’Clinical Trial Updates

22 Jun 2026

UniQure’s chronic epilepsy gene therapy ‘should be on investors’ radar’

uniQure's investigational gene therapy, AMT-260, has shown promising early results in the Phase 1/2a GenTLE trial for refractory mesial temporal lobe epilepsy...

UK MHRA Sets Path for Puberty Blocker Trial to ContinueClinical Trial Updates

22 Jun 2026

UK MHRA Sets Path for Puberty Blocker Trial to Continue

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) have approved the continuation of the controversial...

Shionogi and F2G Report Positive Top Line Data from Phase III OASIS StudyClinical Trial Updates

19 Jun 2026

Shionogi and F2G Report Positive Top Line Data from Phase III OASIS Study

Shionogi and F2G announced positive top-line results from their global Phase III OASIS study, evaluating the oral antifungal drug olorofim for adults with...

Edgewise reports positive top-line results from Phase II CIRRUS-HCM trialClinical Trial Updates

18 Jun 2026

Edgewise reports positive top-line results from Phase II CIRRUS-HCM trial

Edgewise Therapeutics announced positive top-line data from Part D of its 12-week Phase II CIRRUS-HCM trial for EDG-7500, a cardiac sarcomere modulator, in...

Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple ProgramsClinical Trial Updates

18 Jun 2026

Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs

Gelteq Limited provided a corporate update detailing significant progress in the first half of 2026. Key milestones include the planning completion for a human...

Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic CancerClinical Trial Updates

18 Jun 2026

Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer

Elicio Therapeutics reported preliminary clinical observations showing complete radiographic and metabolic responses in three metastatic mKRAS pancreatic...

Be Bio bins hemophilia B cell therapy trial—the biotech’s lead programClinical Trial Updates

18 Jun 2026

Be Bio bins hemophilia B cell therapy trial—the biotech’s lead program

Be Biopharma has terminated its early-stage Phase 1/2 BeCoMe-9 study for BE-101, an autologous B cell therapy targeting hemophilia B. The decision, affecting a...

J&J’s Multiple Myeloma Therapies Impress with New Data at EHA26Clinical Trial Updates

17 Jun 2026

J&J’s Multiple Myeloma Therapies Impress with New Data at EHA26

Johnson & Johnson presented new data for its approved multiple myeloma (MM) therapies, Talvey (talquetamab) and Tecvayli (teclistamab-cqyv), at the European...

BeOne Medicines' Oral Beqalzi and Brukinsa Combination Shows Promise in First-Line CLL/SLLClinical Trial Updates

17 Jun 2026

BeOne Medicines' Oral Beqalzi and Brukinsa Combination Shows Promise in First-Line CLL/SLL

BeOne Medicines presented promising results for its all-oral combination of Beqalzi (BCL2 inhibitor) and Brukinsa (BTK inhibitor) as a first-line treatment for...

Lilly reports Phase III BRUIN CLL-322 trial results for Jaypirca comboClinical Trial Updates

16 Jun 2026

Lilly reports Phase III BRUIN CLL-322 trial results for Jaypirca combo

Eli Lilly and Company announced positive results from its Phase III BRUIN CLL-322 trial, evaluating Jaypirca (pirtobrutinib) combined with venetoclax and...

DemeRx Cleared by FDA for First U.S. Clinical Trial of NoribogaineClinical Trial Updates

16 Jun 2026

DemeRx Cleared by FDA for First U.S. Clinical Trial of Noribogaine

DemeRx is launching the first U.S. clinical trial for its ibogaine-derived drug candidate, noribogaine, following FDA clearance for first-in-human testing in...

Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic CancerClinical Trial Updates

16 Jun 2026

Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer

Elicio Therapeutics reported results from its Phase 2 AMPLIFY-7P study of ELI-002 7P in adjuvant mKRAS-driven pancreatic cancer. The study did not meet its...

Neumora discards depression asset, lays off staffers after pair of late-stage flopsClinical Trial Updates

16 Jun 2026

Neumora discards depression asset, lays off staffers after pair of late-stage flops

Neumora Therapeutics is laying off 35% of its workforce and discontinuing its oral drug candidate, navacaprant, for major depressive disorder (MDD) after it...

Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic diseaseClinical Trial Updates

16 Jun 2026

Rhythm’s obesity drug scores ‘better than expected’ weight loss in rare genetic disease

Rhythm Pharmaceuticals announced positive Phase 2 results for its weight loss injection, Imcivree (setmelanotide), in patients with Prader-Willi syndrome. At...

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with HypoparathyroidismClinical Trial Updates

13 Jun 2026

Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism

Ascendis Pharma announced positive Week 182 data from its completed Phase 3 PaTHway Trial for TransCon PTH (palopegteriparatide) in adults with...

New TALVEY® (talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myelomaClinical Trial Updates

13 Jun 2026

New TALVEY® (talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

Johnson & Johnson announced positive Phase 3 MonumenTAL-3 study results for TALVEY (talquetamab) in combination with daratumumab, with or without pomalidomide,...

Page 1 of 13Next →